The emergence of multidrug resistant microorganisms has triggered the impending need of developing effective antibacterial strategies. Staphylococcus epidermidis and the more virulent S. aureus are able to colonize and form biofilms on implanted medical devices causing clinical acute and chronic infections.
Introduction
To date, most of the research concerning the discovery of new antibacterial agents has been based on the spreading of bacteria within liquid media, and not considering that this method is useful for the prediction of antimicrobial activity against acute infections only characterized by planktonic bacteria.
1 Unfortunately, less than 0.1% of the total microbes spreads in the planktonic mode of growth, whereas most of the microbial species are attached to a living or abiotic surface and organized in aggregates, surrounded by an extracellular matrix, that are termed biolms.
2 Most microorganisms can grow in biolms, including bacteria (Gram-positive and Gram-negative; aerobic and anaerobic), 2 mycobacteria 3 and fungi (mould and yeast).
4,5
Due to the physical and biological properties of the biolm, microorganisms can establish persistent infections with an extreme resistance to the antimicrobial agents (about 100-1000 times), 6 as well as an exceptional ability to evade the host defence. [7] [8] [9] [10] Indeed, the hyper-mutability of the biolm growing bacterial cells during chronic infection and the high tolerance to the common antimicrobial agents make treatment very difficult if not impossible. 11, 12 In particular, for infections related to contaminated medical implants with a biolm, the surgical removal of the prosthesis is oen the only recommended practice. 13 Thus, preventive approaches should be undertaken but, unfortunately, early biolm formation generates very little inammation, making it difficult to detect the initial infection. Antimicrobial tolerance of bacteria growing in biolms is multifactorial and concerns several resistance mechanisms: (i) a lower diffusion of antimicrobial agents through the biolm polysaccharide matrix; 14 (ii) physiological and phenotypic changes of the cell population due to the different nutrient availability within the layers of the biolm; 15 (iii) communication between bacteria of the same or different species, also called quorum sensing (QS); 16 and (iv) expression of efflux pumps (EPs).
Bacterial EPs are transmembrane proteins, grouped in ve different families, 18 present in almost all bacterial species; their function is to extrude structurally unrelated noxious agents before they reach their target. [19] [20] [21] [22] [23] In detail, a basal expression and, especially, an overexpression of EPs in bacteria lead to a rapid efflux of antibacterials from the microbial cells, resulting in a reduced concentration at the target site. In turn, this EPmediated sub-inhibitory concentration of antimicrobials is the reason for an increasing rate of new mutations generating further resistance mechanisms. 24 Interestingly, in recent years, EPs have been described to be involved in several different resistance mechanisms, but their role is not yet clearly understood. Among these results, of particular interest is their involvement in the biolm formation of different microbes (Escherichia coli, Pseudomonas putida, Klebsiella pneuomoniae, and Staphylococcus aureus), indirectly shown by inhibiting EPs with known EP inhibitors (i.e. phenylalanine-arginine betanaphthylamide -PAbN, thioridazine -TZ, carbonyl cyanide 3-chlorophenylhydrazone -CCCP, and 1-(1-naphthylmethyl)-piperazine -NMP). Unfortunately, their activity is thought to be related with nonspecic mechanisms of efflux inhibition and oen also coupled with a high toxicity. [25] [26] [27] Further, EPs involvement in biolm formation was clearly proved through genetic studies in Gram-negative bacteria by the demonstration that deletions of EP genes impaired the production of biolm.
25,26
In S. aureus, a well-known pathogen growing in biolm and causing tremendous chronic infections in patients with prostheses or cystic brosis, 28 the most expressed EP is NorA encoded by the norA gene. 29 The NorA pump is a cytoplasmic membrane protein belonging to the Major Facilitator Superfamily and it uses a proton motive force to energize the transport of antimicrobial agents (e.g. ciprooxacin -CPX) across the cell membrane via an H + /drug antiporter mechanism. 30 The inhibition of NorA is a promising strategy aimed to block drug extrusion from the bacterial cells, but the lack of a crystal structure of NorA makes difficult the medicinal chemistry efforts to nd efficient NorA efflux pump inhibitors (EPIs). Furthermore, the few known NorA EPIs differ in terms of shape and structure and to date their mechanism of action has not been fully claried. Anyway, given our experience in the design and synthesis of NorA EPIs, [31] [32] [33] [34] in this work we investigated the capability of previously reported potent NorA EPIs 32-34 to inhibit biolm formation in different Staphylococcus strains. To the best of our knowledge, few examples of biolm formation inhibition by EPIs in S. aureus have been reported so far, and, in any case, they concern the use of known and toxic compounds such as CCCP and TZ.
26,27
In addition, because of the presence of a norA gene codifying for a NorA-like efflux pump in Staphylococcus epidermidis, 35 our study was also enlarged to S. epidermidis, which is less virulent than S. aureus, but also able to colonize and to form biolms on implanted medical devices and cause several clinical infections. Anyway, the ability of both Staphylococcus spp to form biolms on an abiotic surface or damaged host tissue is an important virulence factor that represents one of the main survival mechanisms for the bacteria.
36
Thus, with the aim to nd dual EP-biolm formation inhibitors, we selected four of the in house most potent NorA EPIs (three 2-phenylquinolines 1a-c 32, 33 and a pyrazolobenzothiazine 2 34 Fig. 1 ), in order to assess their ability to inhibit biolm formation and/or induce biolm dispersal on S. aureus (ATCC 29213) and S. epidermidis (ATCC 35984).
The obtained encouraging results prompted us to assess two out of the four compounds in combination with CPX in order to demonstrate their ability, in synergism with CPX, in preventing biolm formation with Staphylococcus strains.
Then, once we have proved that synthetic EPIs can synergize with CPX in reducing biolm formation, looking to future medicinal chemistry efforts aimed to identify compounds endowed with both EPI and biolm inhibition activity, we have shown that a S. aureus (SA-1199B overexpressing norA gene) strain, 37 commonly used to identify new NorA EPIs in preliminary screenings, produced a greater biolm mass than its parent wild-type strain SA-1199. 37 In parallel, the same two strains were grown in the presence of the two best NorA EPIs in an attempt to prove that, by blocking EPs, it is possible to signicantly reduce biolm mass in the overexpressing EP strain SA-1199B. and 1c 33 ) and pyrazolobenzothiazine 2 34 ( Fig. 1) were selected from our in house library of NorA EPI compounds and tested to assess their inhibition activity on biolm formation. All the stock solutions of the compounds were prepared during the day of the experiment in DMSO (10 mg mL À1 ), with the exceptions of CPX, which was dissolved with sterile water. Further dilutions were set up with the medium. 
Microbial strains and growth conditions
The microbial strains used in this study were S. aureus (ATCC 29213), S. aureus SA-1199B (overexpressing norA and also possessing an A116E GrlA substitution), 37 its isogenic parental strain SA-1199 (norA wt), 37 and S. epidermidis (ATCC 35984 bacteria per well. The plates were incubated at 37 C for 24 h.
The MIC of each compound was dened as the lowest concentration that inhibited visible growth of the microorganisms and bacterial growth was also determined by spectrophotometer analysis (600 nm). MIC assays were performed in duplicate and each experiment was repeated at least twice.
Effect of NorA EPIs on biolm formation
The in vitro static biolm assay was performed using a 96-well microtiter plate as previously described, but with some modications. 39, 40 To grow biolms, overnight cultures of S. aureus or S. epidermidis were diluted 1 : 100 (corresponding to 1-2 Â 10 6 CFU mL À1 ) in TSB supplemented with 2% sucrose. Bacteria were incubated in the presence or absence of different NorA EPIs (1a-c 32,33 and 2
34
) at concentrations of 250, 125, 62.5, 25, and 2.5 mg mL
À1
; TZ (at 250, 125, 62.5, 25, and 2.5 mg mL À1 ) and CPX at 0.45 mg mL À1 were used as the positive controls. Cultures were incubated at 37 C for 24 h in static conditions. Aer incubation, the biolm developed in each well was washed twice with 200 mL of distilled water. In each well, 100 mL of 0.4% crystal violet were added for 30-45 min. Aer this procedure, the wells were washed four times with distilled water, immediately discoloured with 200 mL of 95% ethanol. Aer 45 minutes, 100 mL of discoloured solution was transferred to a well of a new plate and the crystal violet measured at 570 nm in a microplate reader (TECAN). The amount of biolm formed was measured by comparing the absorbance values of the compound-treated wells versus untreated control wells. Biolm assays were performed in triplicate in at least three individual experiments for each concentration.
Effect of NorA EPIs on biolm dispersion
To test the effect of NorA EPIs on biolm dispersion, biolms, grown on the inside surface of 96-well microtiter plates for 24 h as described above, were treated with three different concentrations (1 Â MIC, 2 Â MIC, and 4 Â MIC; when MIC values were >250 mg mL
À1
, the used MIC value was 250 mg mL
) of NorA EPIs (1a-c 32, 33 and 2
34
) at 37 C for further 24 h. Diluent of NorA EPIs was used as a control. The positive controls were TZ and CPX. Aerward, the biolm mass was quantied by crystal violet assay. Biolm dispersal assays were performed in triplicates in at least three individual experiments for each concentration.
Checkerboard assays
The synergism of the NorA EPIs (1c 33 and 2
34
) with CPX was evaluated by a checkerboard titration assay in microplates as recommended by the NCCLS and expressed as the sum of the fractional inhibitory concentration (FIC) index for each agent. In brief, checkerboards were set up with double dilutions of CPX (0-1.8 mg mL À1 ) in the horizontal wells and NorA EPIs (0-250 mg mL À1 ) in the vertical wells. Then, a 100 mL suspension of S. aureus or S. epidermidis adjusted to 10 5 /10 4 CFU mL À1 was added to each well and cultured at 37 C for 24 h in MHB.
Aer incubation, plates were visually inspected for turbidity to determine growth. Visual readings of the MIC were then performed and the OD 600 nm values were measured. Experiments were performed in triplicate on different days. Each checkerboard test generates many different combinations and, by convention, the FIC value of the most effective combination was used in calculating the fractional inhibitory concentration index (FICI). FICI was calculated by adding both FICs: are concentrations of compounds A and B at the isoeffective combinations. The FICI was interpreted as synergistic when it was #0.5, antagonistic when it was >4.0, and any value between was interpreted as indifferent. Aer the FICI determination, planktonic cells were removed and the biolm attached to the bottom of the well was stained by Cristal Violet as described above. The reduction of the biolm was evaluated in wells where cultures were treated with the combination of compounds two fold lower than the FICI.
Cell lines
HeLa cell line (ATCC CCL-2), a human epithelial carcinoma cell line derived from cervical cancer, and HepG2 (ATCC HB-8065), a human liver cancer cell line, were maintained in RPMI 1640. The culture medium consisted of RPMI 1640 with 2 mM glutamine, 10% fetal bovine serum (FBS), 10 000 penicillin units and streptomycin 10 mg mL À1 , referred to as cRPMI.
Conuent cultures were split using 0.25% trypsin/EDTA. Monolayers were incubated at room temperature for 5-10 min until cell detachment. Fresh medium (cRPMI) was added to disperse the cells, suspensions were then centrifuged and resuspended in culture medium at the desired concentration. Human cervical cancer HeLa (ATCC CCL-2) and human hepatocellular carcinoma HepG2 (ATCC HB-8065) cell lines were obtained from LGC standards (Milan, Italy).
Cytotoxicity assay
The cytotoxicity of NorA EPIs (1a-c 32,33 and 2 34 ), TZ, and CPX was tested by the determination of the cell ATP level by a ViaLight® Plus Kit (Lonza). The method is based upon the bioluminescent measurement of ATP that is present in all metabolically active cells. The bioluminescent method utilizes an enzyme, luciferase, which catalyses the formation of light from ATP and luciferin. The emitted light intensity is linearly related to the ATP concentration and is measured using a luminometer. To perform cytotoxicity tests, cells were recovered, counted and adjusted to the concentration 2 Â 10 5 /mL, seeded in a at bottom 96-well culture plate and incubated until monolayer formation. The examinations were carried out for the test compounds and the control (cells not treated). Various 1 : 2 dilutions of the above mentioned NorA EPIs were diluted 1 : 2 in cRPMI in order to achieve nal concentrations in the wells from 250 to 0.11 mg mL
À1
. Each concentration was tested in triplicate. In parallel, the cytotoxicity of CPX-1c (0.056-3.9 and 0.014-31.25 mg mL
, respectively) and CPX-2 (0.00356-15.625 and 0.028-7.8 mg mL À1 , respectively) combinations were tested on HepG2 cells. Aer adding the test compounds onto cell monolayers, plates were incubated for 24 h at 37 C. Aer incubation, plates were le to cool at room temperature for 10 minutes and then the Cell Lysis Reagent was added to each well to extract ATP from the cells. Next, aer 10 minutes the AMR Plus (ATP Monitoring Reagent Plus) was added and aer 2 more minutes the luminescence was read using a microplate luminometer (TECAN). The results are expressed as 50% cytotoxic concentration (CC 50 ), dened as the concentration required to reduce the live cell number by 50% compared to the untreated controls. Cytotoxicity values referred to the combination of CPX plus 1c 33 or 2 34 assessed at their FICI values and were expressed as percentage of live cells.
Statistical analysis
All the data were expressed as mean AE SD. Differences between groups were compared using the Student's t-test (two-tailed). A P-value of <0.05 was considered signicant.
Results & discussion

Antimicrobial activity of NorA EPIs
The MICs of the four NorA EPIs (the 2-phenylquinolines 1a-c 32, 33 and the pyrazolobenzothiazine 2 34 Fig. 1 ) and TZ were rstly determined on S. aureus (ATCC 29213) and S. epidermidis (ATCC 35984). Data shown in Table 1 illustrate how the selected compounds had generally no intrinsic antibacterial activity with MIC values equal to or higher than 250 mg mL À1 , with the exception of 1b 33 that showed a MIC value of 62.5 mg mL À1 when tested against S. epidermidis. On the contrary, both the strains were susceptible to CPX, according to CLSI breakpoints. CPX was included in the test as a positive control. Since resistance develops only for compounds endowed with antibacterial activity, high MIC values for NorA EPIs were considered favourably.
Anti-biolm activity
To evaluate if the NorA efflux pump inhibition could inuence the biolm formation of S. aureus and S. epidermidis, biolms were grown in the absence or presence of NorA EPIs (1a-c 32, 33 and 2) 34 and TZ at different concentrations (250, 125, 62.5, 25 and 2.5 mg mL À1 ) and the biolm mass was analysed by Cristal
Violet staining. The results in Fig. 2 show a similar trend of activity for NorA EPIs on both the strains tested.
In particular, with respect to S. aureus, compounds 1a 32 and 1b 33 were able to reduce the biolm by 50% only at the concentrations corresponding to MIC. On the contrary, of considerable interest, compounds 1c 33 and 2 34 at concentrations corresponding to 1/2 and 1/4 MICs showed a biolm mass decrease greater than 60%, comparable to that observed for TZ. Then, at lower concentrations, only compound 2 34 was again able to reduce biolm formation, by 60% at 25 mg mL À1 (1/10 MIC) up to 30% at 2.5 mg mL À1 (1/100 MIC), the same as the positive control TZ. Similar results were observed on S. epidermidis, where 2 34 showed an ability to reduce the biolm mass up to 20% at 1/4 MIC, an inhibition higher than that observed for TZ. Compound 1b 33 showed a good biolm inhibition activity against S. epidermidis only when tested at 1Â, 2Â, and 4Â MIC. Noteworthy, biolm inhibition data concerning CPX showed that the antibacterial alone at its MIC is only partially able to reduce biolm formation (Fig. 2) and consequently, once the biolm is formed, CPX antibacterial activity will be hampered; therefore, a synergistic action of CPX with EPIs could increase the antibacterial drug efficacy.
In parallel, the ability of NorA EPIs, TZ, and CPX to disperse preformed biolm was assayed on the same S. aureus and S. epidermidis strains, grown in biolms, for 24 h (Fig. 3) , by using 1Â MIC concentrations for all the tested compounds. The results in Fig. 3A show that compound 2 34 exhibited a good dispersal activity (50% mass reduction) at 1 Â MIC, comparable to that observed for the reference TZ and much better than that of antibacterial CPX. Compounds 1a-c 32,33 were able to reduce a S. aureus preformed biolm by 48.26, 34.37 and 50.70%, respectively, only at a very high concentration (4 Â MIC -data not shown). Considering S. epidermidis, EPI compounds 1b, 33 1c 33 and 2 34 showed a good dispersal activity while compound 1a 32 was the worst of the four with the percentage of mass biolm reduction corresponding to only 20% (Fig. 3B) . In detail, 1b 33 and 1c 33 exhibited an activity comparable to that observed for TZ with a 50% reduction of preformed biolm mass and compound 2 34 showed the best activity comparable to that of the antibacterial CPX alone with a 65% reduction of the biolm mass.
Synergistic antibiolm activity of NorA EPIs with CPX
With the aim to consider a feasible medical application, two of the four EPIs (1c 33 and 2 34 ) having the best biolm inhibition activity were tested in synergism with CPX on S. aureus ATCC 29213 and S. epidermidis ATCC 35984 forming biolms in order to evaluate their ability to improve the anti-biolm effect of CPX.
Calculations of FIC and FICI (always less than 0.5) obtained by checkerboard assays on S. aureus and S. epidermidis showed signicant synergistic effects of NorA EPIs (1c 33 and 2 
34
) with CPX ( Table 2) .
Since a basal expression of EPs contributes to the CPX MIC increase and according to the previously reported EPI activity of compounds 1c 33 and 2, 34 the data shown in Table 2 highlight that, for both strains, EPI compounds completely synergize with CPX in a dose-dependent manner.
Data were collected by using strains enabled to grow in biolm in order to check the concentrations at which compounds did not possess an antimicrobial effect (1/2 FICI values). Indeed, bactericidal concentrations do not allow monitoring of the combined EPI-CPX ability to inhibit biolm formation because, of course, bacteria are killed when still in the planktonic mode. Therefore, at concentrations two-fold lower than FICI values, the planktonic cells were removed from the wells and the production of biolm on the bottom of the well was evaluated. The biolm reduction was calculated as a percentage in comparison with untreated bacterial cells. Compound 1c 33 in combination with CPX showed an inhibition of the biolm equal to 60% against both Staphylococcus strains, while compound 2 34 plus CPX highlighted a 60% biolm inhibition against S. epidermidis and an even greater (74%) biolm inhibition against S. aureus, highlighting that at very low concentrations NorA EPIs in combination with CPX are able Fig. 2 Effect of NorA EPIs (1a-c and 2) on the biofilm formation of S. aureus (ATCC 29213) and S. epidermidis (ATCC 35984). TZ was used as a positive control. CPX was used at its MIC to evaluate its ability to inhibit biofilm. Data represent the mean AE SD of two independent experiments performed in triplicate. *P < 0.05 (NorA EPI-treated or CPX-treated microorganisms vs. untreated bacteria). to inhibit biolm formation in Staphylococcus strains. Therefore, it is evident that known NorA inhibitors could be used with a dual effect: (i) to avoid the extrusion of CPX from S. aureus cells, as previously reported, and (ii) to abolish biolm formation thereby allowing CPX to carry out the bactericidal effect. In this way, all of the NorA EPIs could be thought as putative S. aureus biolm inhibitors. Moreover, worthy of note is the prophylactic purpose that low doses of CPX plus a NorA EPI can prevent the biolm formation that, otherwise, once formed, is almost impossible to eradicate.
Biolm formation evaluation in different S. aureus strains (SA-1199/SA-1199B)
Driven by the encouraging results obtained, we decided to monitor the biolm production in the absence or presence of the two best compounds (1c 33 and 2 
34
) against SA-1199B, 37 a S. aureus strain commonly used by microbiologists to demonstrate the inhibition of the NorA pump. Indeed, due to the overexpression of the norA gene and mutation in A116E GrlA, 37 the SA-1199B strain is commonly used (i) to evaluate the NorA EPI activity by inhibition of the ethidium bromide efflux, a dye NorA substrate, and (ii) to prove the synergistic effect in restoring antimicrobials MIC through checkerboard assays with antimicrobial agents substrates of the NorA pump. [32] [33] [34] Therefore, we employed this strain to verify the inhibition of the biolm formation in correlation with the NorA EP inhibition and indirectly show the correlation between NorA overexpression and biolm formation. Thus, biolm production of SA-1199B
37 was compared to that of its parental strain SA-1199 norA wild-type 37 and the results show that SA-1199B 37 was able to form the biolm with a mass signicantly higher (P < 0.01) than its parental wild-type strain SA-1199 37 (Fig. 4) . Moreover, when the biolm production was monitored in the presence of NorA EPIs, 1c 33 (Fig. 4) . As a consequence, the presence of EPIs reduced the biolm formation of the SA-1199B 37 strain to the same level as SA-1199, 37 highlighting that EP overexpression takes part in the mechanism involved in biolm formation. Moreover, from these data it is evident that inhibiting the NorA EP activity with EPIs could be a promising strategy to decrease the biolm formation of S. aureus strains.
Cytotoxicity evaluation
For all the EPIs reported in this study, cytotoxic activity on both human epithelial (HeLa) and human liver (HepG2) cancer cells was evaluated by measurement of the ATP levels ( in combination with CPX against both Staphylococcus strains. In the same way, the CC 50 values of compound 1c 33 were higher than the concentration used in combination with CPX against S. epidermidis but, unfortunately, not against the S. aureus strain.
Thus, in order to conrm the safety prole of these combinations, the cytotoxicity of CPX plus 1c 33 or 2 34 at the concentrations corresponding to the FICI values resulting from checkerboard assays were evaluated on HepG2 cells. With the exception of the combination CPX-1c against S. aureus, all the combinations CPX-EPI showed a 100% of cell vitality (Table 4) . Therefore, it can be concluded that compound 2 34 can be used in combination with antimicrobials at sub-toxic concentrations for human cells to prevent biolm formation.
Conclusions
In this paper, we show that the biolm formation of S. aureus and S. epidermidis strains can be affected by using synthetic NorA EPIs. Further, in order to collect data about the possible involvement of NorA EP in S. aureus biolm formation, we show that potent NorA EPIs possess the ability to decrease biolm mass in a S. aureus strain overexpressing norA (SA-1199B).
37
Although the mechanism is still unclear, these data indirectly conrm that the NorA EP is involved in the formation of biolm, highlighting its role as virulence factor.
Finally, data collected in this study suggest that potent EPIs, used in synergism with CPX, increase the efficiency of the antibacterial in preventing biolm formation in Staphylococcus strains, presumably through EP inhibition. Thus, a starting point for an innovative research eld addressed to restore the antibacterial activity of old ineffective drugs has been identied. Moreover, this method to combine dual EP/biolm inhibitors with antimicrobial agents should be considered for the production of lm to spread on materials requiring sterility with the aim to prevent biolm formation.
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